IST-477 / Isosterix - LARVOL DELTA

Discovery and development of IST-477, a selective KAT6A histone acetyl transferase inhibitor and characterization of its anti-tumor efficacy in ER+ HER2- breast cancer and other tumor indications (AACR 2025) - "An inhibitor of KAT6A and KAT6B, PF-07248144, has entered phase 2 clinical studies with durable partial responses reported in estrogen-receptor positive (ER+) HER2- breast cancer patients who had progressed on a prior endocrine therapy and CDK4/6 inhibitor (Mukohara et al, 2024, Nature Medicine 30:2242). Pharmacologic efficacy of this targeted therapeutic will be discussed with an analysis of the relationship to KAT6A and 6B expression in these models. All IND-enabling studies to support clinical progression of IST-477 are planned for completion in mid-2025."

Clinical • Epigenetic controller • Breast Cancer • Esophageal Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • KAT6A • KAT6B